Niagen Bioscience reports 30% net sales growth to $129.4M in 2025; net income up 103% to $17.4M

Niagen Bioscience, Inc.

Full year 2025 net sales $129.4M (+30% YoY); net income $17.4M (+103%); adjusted EBITDA $20.4M (+139%).
Q4 net sales $33.8M (+16% YoY); Q4 net income $4.1M vs $7.2M prior; Q4 adjusted EBITDA $4.1M (+$0.7M).
Gross margin improved 250 bps to 64.3% for year; cash $64.8M at Dec 31, 2025.
FY 2026 net sales outlook 10-15% growth ex. reference standards segment sold in Feb 2026 for ~$6M.
Acquired foundational NR patent portfolio from Queen’s University Belfast (Dec 2025); launched Tru Niagen Beauty (Nov 2025).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.